Janssen-Cilag

janssen-cilag.ch
+41417673434

Janssen-Cilag AG

Sihlbruggstrasse 111
6341 Baar
Switzerland
+41417673434
janssen-cilag.ch
Profile News

About Janssen-Cilag

Janssen-Cilag AG operates as a pharmaceutical company. It develops pharmaceutical in the fields of analgesia, gynecology, dermatology, hematology, oncology, urology, gastroenterology, neurology, psychiatry, and virology. The company was founded in 1994 and is based in Zug, Switzerland. Janssen-Cilag AG operates as a subsidiary of Johnson & Johnson

Read more about Janssen-Cilag
Facts about Janssen-Cilag
  • Industry : Pharma

News about Janssen-Cilag

Janssen-Cilag

15-Jun-2020 | research and development

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

Phase 1/2a Clinical Trial to Begin in Second Half of July

Read news
Janssen-Cilag

05-Jul-2012 | research and development

Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)

The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of ...

Read news
Janssen-Cilag

13-Sep-2010 | research and development

Discontinuation of sale of ceftobiprole in Switzerland

Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the ...

Read news
Janssen-Cilag

29-Jun-2010 | research and development

European CHMP concludes re-examination of ceftobiprole

Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV, a Johnson & Johnson ...

Read news
Janssen-Cilag

23-Feb-2010 | research and development

European CHMP adopts negative opinion on ceftobiprole

Basilea Pharmaceutica Ltd. announced that the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing ...

Read news
Janssen-Cilag

02-Sep-2008 | research and development

INTELENCE (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy

The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) (etravirine). INTELENCE is a next ...

Read news
Janssen-Cilag

19-Jun-2007 | research and development

Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole

Basilea Pharmaceutica Ltd. announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by ...

Read news
Show more news about Janssen-Cilag

Here you will find Janssen-Cilag AG